in vivo
Experimental TherapeuticsIn Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosisThe riminophenazine agent clofazimine (CFZ) is repurposed as an important component of the new short-course multidrug-resistant tuberculosis regimen and significantly shortens first-line regimen for drug-susceptible tuberculosis in mice. However, CFZ use is hampered by its unwelcome skin discoloration in patients.
PharmacologyEvaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosisMulti- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment of Mycobacterium tuberculosis.
SusceptibilityImplications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models...Candida tropicalis isolates often display reduced but persistent growth (trailing) over a broad fluconazole concentration range during EUCAST susceptibility testing. Whereas weak trailing (<25% of the positive growth control) is common and found not to impair fluconazole efficacy, we investigated if more pronounced trailing impacted treatment efficacy.
Letter to the EditorImmunosuppressed Adult Zebrafish Model of Mucormycosis- Experimental TherapeuticsIn Vitro, In Silico, and In Vivo Analyses of Novel Aromatic Amidines against Trypanosoma cruzi
- Experimental TherapeuticsIn Vitro and In Vivo Studies of the Trypanocidal Effect of Novel Quinolines
- Experimental TherapeuticsAdjuvant Antibiotic Activity of Acidic Sophorolipids with Potential for Facilitating Wound Healing